Search

Home > New FDA Approvals > 082 – Gilead 3-drug Biktarvy for HIV: FDA statement on Kratom; THX-110 for Tourette's syndrome; PT-112 for R/R myeloma
Podcast: New FDA Approvals
Episode:

082 – Gilead 3-drug Biktarvy for HIV: FDA statement on Kratom; THX-110 for Tourette's syndrome; PT-112 for R/R myeloma
Category: Science & Medicine
Duration: 00:09:29
Publish Date: 2018-02-08 07:00:00
Description:

February 8, 2018

1:32 FDA approves Gilead's three-drug HIV regimen https://www.reuters.com/article/gilead-sciences-fda/u-s-fda-approves-gileads-three-drug-hiv-regimen-idUSL4N1PX5P7

2:17 Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm595622.htm 

4:10 Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected https://www.prnewswire.com/news-releases/therapix-biosciences-completes-pre-ind-communication-with-fda-on-thx-110-for-tourette-syndrome-clinical-development-to-proceed-as-projected-300594991.html 

7:00 Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation https://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-first-cohort-enrolled-in-phase-i--ii-trial-of-pt-112-in-relapsed--refractory-multiple-myeloma-and-receipt-of-fda-orphan-drug-designation-300594539.html

Please check out http://www.newfdaapprovals.com
Total Play: 0